Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler® Knotless Anchor System and Innovative Bridgeline™ Tape
05 Janvier 2024 - 2:00PM
Business Wire
Paragon 28, Inc. (NYSE: FNA), is thrilled to announce the launch
of the Grappler® Knotless Anchor System and Bridgeline™ Tape,
enhancing the Company’s position in the fast-growing foot and ankle
specific soft tissue market in 2024 and beyond. Both the Grappler®
Knotless Anchor System and Bridgeline™ Tape are highly
complementary to a broad range of Paragon 28’s existing hardware
products with several applications spanning multiple foot and ankle
indications.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240105897232/en/
Figure 1: Grappler® Knotless Anchor
System and Bridgeline™ Tape (Photo: Business Wire)
The Grappler® Suture Anchor System is a sterile packed kit that
includes all instrumentation needed to complete each case in
multiple configurations designed to reduce waste and interoperative
complexity.
Surgeon designer, Mark Prissel, DPM commented, “The Grappler®
Suture Anchor System is a comprehensive soft tissue anchoring
product line that includes implants designed by and for foot and
ankle surgeons for acute and chronic repairs. The implant sizes,
suture lengths, and instrument ergonomics are all ideally equipped
for efficient utilization in common tendon and ligament procedures,
while complementing the broader Paragon 28 product portfolio
seamlessly.”
The Bridgeline™ Tape is a huge leap forward in soft tissue
stabilization. The tape features a novel semi-resorbable material
with the ability to transition from rigid at the early stages of
healing to a more natural physiological state. This product’s
ability to transition over time is truly unique and is believed to
foster better healing characteristics and expected to result in
improved patient outcomes.
“We continue to believe soft tissue will play an increasingly
important role in improving foot and ankle patient outcomes, and we
could not be more excited to bring two new solutions to market to
start the year. Many of the procedures we aim to treat at Paragon
28 involve some element of soft tissue compromise and we expect
both of these products to be complementary to a large portion of
our portfolio,” commented Albert DaCosta, Paragon 28’s CEO. “I am
especially proud of what we accomplished with the Bridgeline™ Tape.
With that product, we set out with a desire to create an optimal
environment for healing with less scarring and we believe this
unique solution accomplishes that goal and, importantly, will
result in optimal treatment for each patient.”
The Grappler® Knotless Anchor System and Bridgeline™ Tape
bolsters Paragon 28’s soft tissue offering which includes the
Paratrooper™ Plantar Plate System, TenoTac™ 2.0 Soft Tissue
Fixation System, Grappler® Interference Screw System, and Grappler
Soft Tissue Anchor System. With this comprehensive portfolio,
Paragon 28® provides its customers with a single source to address
their foot and ankle soft tissue needs.
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28, Inc. is a leading medical
device company exclusively focused on the foot and ankle orthopedic
market and is dedicated to improving patient lives. From the onset,
Paragon 28® has provided innovative orthopedic solutions,
procedural approaches and instrumentation that cover a wide range
of foot and ankle ailments including fracture fixation, forefoot,
ankle, progressive collapsing foot deformity (PCFD) or flatfoot,
Charcot foot and orthobiologics. The company designs products with
both the patient and surgeon in mind, with the goal of improving
outcomes, reducing ailment recurrence and complication rates, and
making the procedures simpler, consistent, and reproducible.
Forward Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to: Paragon 28’s potential to shape a better future
for foot and ankle patients. You are cautioned not to place undue
reliance on these forward-looking statements. Forward-looking
statements are only predictions based on our current expectations,
estimates, and assumptions, valid only as of the date they are
made, and subject to risks and uncertainties, some of which we are
not currently aware. Forward‐looking statements should not be read
as a guarantee of future performance or results and may not
necessarily be accurate indications of the times at, or by, which
such performance or results will be achieved. These forward‐looking
statements are based on Paragon 28’s current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward‐looking statements as a result of these
risks and uncertainties. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Paragon 28’s business in general, see Paragon 28’s
current and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2022 and its Quarterly Reports on Form
10-Q, as updated periodically with its other filings with the SEC.
These forward-looking statements are made as of the date of this
press release, and Paragon 28 assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
Disclaimer
Dr. Prissel may report consulting and royalty fees from Paragon
28 in connection with the provision of product development services
to Paragon 28.
Nothing in this material is intended to provide specific medical
advice or to take the place of written law or regulations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240105897232/en/
Investor Contact
Matthew Brinckman Senior Vice President, Strategy and Investor
Relations Phone: (720) 912-1332
Paragon 28 (NYSE:FNA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Paragon 28 (NYSE:FNA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024